Avecho Biotechnology Limited (ASX:AVE)
Australia · Delayed Price · Currency is AUD 0.0190
0.00 (0.00%)
Jul 31, 2026, 4:12 PM AEST
Avecho Biotechnology Balance Sheet
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.66 | 2.37 | 5.5 | 1.47 | 3.26 |
Cash & Short-Term Investments | 4.66 | 2.37 | 5.5 | 1.47 | 3.26 |
Cash Growth | 96.40% | -56.86% | 274.90% | -55.03% | 74.33% |
Accounts Receivable | 0.16 | 0.57 | - | - | 0.04 |
Other Receivables | 2.05 | 1.68 | 1.1 | 0.75 | 1.09 |
Receivables | 2.2 | 2.25 | 1.1 | 0.75 | 1.13 |
Inventory | 0.01 | 0.14 | 0.1 | 0.4 | 0.2 |
Prepaid Expenses | - | - | - | 0.23 | 0.22 |
Other Current Assets | 0.18 | 0.05 | 0.3 | 0.01 | - |
Total Current Assets | 7.06 | 4.81 | 7 | 2.85 | 4.81 |
Property, Plant & Equipment | 0.03 | 0.17 | 0.32 | 0.47 | 0.34 |
Other Intangible Assets | - | - | - | 0.03 | 0.1 |
Other Long-Term Assets | 0.02 | 0.02 | - | - | - |
Total Assets | 7.11 | 5 | 7.32 | 3.35 | 5.25 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.1 | 0.06 | 0.09 | 0.19 | 0.08 |
Accrued Expenses | 0.56 | 0.56 | 0.49 | 0.46 | 0.42 |
Short-Term Debt | - | 0.98 | - | - | - |
Current Portion of Leases | 0.01 | 0.08 | 0.08 | 0.07 | 0.08 |
Current Unearned Revenue | - | - | 0.16 | - | - |
Other Current Liabilities | 0.03 | 0.02 | 0.02 | 0.02 | 0.12 |
Total Current Liabilities | 0.71 | 1.71 | 0.84 | 0.75 | 0.7 |
Long-Term Leases | - | 0.01 | 0.1 | 0.18 | 0.01 |
Long-Term Unearned Revenue | 4.83 | - | - | - | - |
Other Long-Term Liabilities | 0 | 0 | - | - | - |
Total Liabilities | 5.55 | 1.73 | 0.94 | 0.92 | 0.71 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 246.9 | 244.61 | 244.61 | 237.53 | 237.6 |
Retained Earnings | -273.81 | -269.39 | -267.44 | -264.1 | -262.07 |
Comprehensive Income & Other | 28.47 | 28.06 | 29.21 | 29 | 29 |
Shareholders' Equity | 1.56 | 3.27 | 6.38 | 2.42 | 4.54 |
Total Liabilities & Equity | 7.11 | 5 | 7.32 | 3.35 | 5.25 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.01 | 1.08 | 0.18 | 0.25 | 0.09 |
Net Cash (Debt) | 4.65 | 1.3 | 5.33 | 1.22 | 3.17 |
Net Cash Growth | 258.21% | -75.65% | 336.06% | -61.46% | 85.80% |
Net Cash Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Filing Date Shares Outstanding | 3,673 | 3,169 | 3,169 | 1,838 | 1,838 |
Total Common Shares Outstanding | 3,673 | 3,169 | 3,169 | 1,838 | 1,836 |
Working Capital | 6.35 | 3.1 | 6.16 | 2.11 | 4.11 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Tangible Book Value | 1.56 | 3.27 | 6.38 | 2.4 | 4.43 |
Tangible Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Machinery | - | - | - | - | 0.55 |
Leasehold Improvements | - | - | - | - | 0.2 |